Purpose: The feasibility, in terms of safety and potential efficacy, of a new drug combination for binocular use as a noninvasive pharmacological solution for treating presbyopia was examined.
INTRODUCTION
Presbyopia, which is due to progressive age-related accommodative loss, begins to affect near visual tasks at around 40 years of age, and is associated with substantial negative effects on vision-targeted health-related quality of life [1] . In 2015, more than 2.5 billion people around the world were aged 40 years or older; given that the global population is growing and ageing, presbyopia will affect even more people in the future [2] . However, the pathophysiology of presbyopia is poorly understood, so the correction of presbyopia and the restoration of accommodation are among the most important targets of ophthalmology research. Although surgical compensation for presbyopia has improved over the past decade, it is still limited, so there has recently been increasing interest in nonsurgical treatments [3] . Topical treatment of presbyopia is an attractive approach which, if available and effective, would be the treatment of choice for many patients. The few potential topical treatments for presbyopia that are currently being studied claim to work on different aspects of the accommodative process, but each of these approaches presents some disadvantages [4] [5] [6] [7] . The topical treatment presented herein contains a parasympathetic, a NSAID, two alpha-agonist agents, and an anticholinesterase agent, is administered bilaterally, and promises to ameliorate the symptoms of presbyopia through pharmacological stimulation of iris and ciliary muscle, thus minimizing the drawbacks associated with a purely parasympathetic action [8] . Here, we report the initial outcomes obtained in a pilot investigation with the new drug combination for binocular use in presbyopic patients.
METHODS
This pilot study was begun after approval was obtained from the ethics committee of Fundació n Oftalmoló gica Vejarano in Popayán, Colombia. Each participant provided written informed consent, and the study followed the tenets of the Declaration of Helsinki. The pharmacological stimulation protocol was developed and submitted for patent in 10 countries by Dr. Vejarano, who had been using his own product and achieving satisfactory results with it for five and a half years previously (since July 2010) [9] . The study group comprised 14 presbyopic subjects (28 Table 1 summarizes the data for some variables of particular interest. Figures 1, 2 were still enjoying the improved near vision that they had after the eye drops were applied, and whether they would like to continue using the eye drops in order to maintain this enhanced near vision. All patients answered affirmatively to the question. No adverse effects were reported. 
RESULTS

DISCUSSION
Several studies have been conducted to determine how much each factor involved in the accommodative process contributes to it [10] [11] [12] [13] [14] . The few topical treatments for presbyopia currently under study claim to work on different aspects of the accommodative process: they involve monovision parasympathetic-mediated miosis and ciliary muscle stimulation or lens softening in order to restore its shape-changing ability [4] [5] [6] [7] . Each of these approaches presents some disadvantages.
Pure parasympathetic treatments result in a rather small pupil diameter and a myopic shift, compromising far distance vision, and they also cause several well-known adverse reactions due to the muscarinic stimulation of ciliary muscle and pupil sphincter [5] . Even a safe lens-softening treatment could be less effective than expected because changes in mechanical properties seem to be less important in the advent and progression of presbyopia than changes in lens geometry [12] . A monovision treatment could reduce visual performance in reduced light conditions compared to a binocular approach [14] . For this reason, the treatment used in our pilot study is instilled in both eyes. The Vejarano (patent pending) eye drops both stimulate the contraction of the ciliary body and maintain a physiological pupil diameter variation. In this context, binocular treatment avoids the worsening of visual performance in reduced light and allows physiological image merging with clear focus at near, intermediate, and distance. Pilocarpine provides both miosis and ciliary body contraction, stimulating accommodation, and may improve tear production by stimulating lacrimal gland secretion [15] . Phenylephrine, nepafenac, and pheniramine, each in different ways and amounts, stop excess pupil constriction and counteract ciliary muscle spasm, vascular congestion, and hyperemia induced by pilocarpine [6, [16] [17] [18] . Naphazoline intensifies the relaxing effect of pilocarpine on dilator pupillae while relieving its side effects, refractive measurements performed in this study showed there was a maximum myopic shift of just 0.5 D, which progressively reduced and disappeared after 3 h. Pupil diameter was also measured and found to be mildly affected by the topical treatment, so the mechanism for near vision improvement might be due to factors other than miosis. However, we cannot clarify this issue based on the evidence provided by the present study, so a controlled study of a 
